Recent Media Coverage
RephImmune: Innovation Meets Urgency in Women’s Cancer Treatment
Embedded Files
RephImmune Joins Tech4Eva 2025 as the Only Taiwan Startup Selected: Recognized for Our Breakthrough T Cell Therapy Targeting Women’s Cancers
RephImmune Biotechnology Inc. is honored to announce our selection into Tech4Eva 2025, Switzerland’s premier global accelerator program focused on innovation in women’s health. Among 195 applicants from 42 countries, RephImmune is proud to be the only startup from Taiwan chosen for this year’s cohort.
Now in its fifth year, Tech4Eva is co-founded by Groupe Mutuel and EPFL Innovation Park and aims to foster cutting-edge solutions in reproductive health, menopause, oncology, maternal care, and healthy aging. This year’s record-breaking number of applicants reflects the growing global demand and investment in femtech, a market projected to exceed $60 billion USD in 2025 and double in the next eight years.
Lan Zuo Gillet, Director of Tech4Eva, stated: “This year, we selected more science-driven femtech startups focused on women-specific cancers and other medical challenges. We believe in bridging the gap between scientific innovation and market implementation.”
RephImmune’s selection recognizes the innovation behind our lead product, RACE-T, a next-generation engineered T cell therapy designed to target ovarian cancer and other solid tumors. RACE-T is engineered to be safer, more durable, and more effective: offering new hope for women battling difficult-to-treat cancers.
Joining Tech4Eva allows RephImmune to connect with leading healthcare institutions, investors, and experts worldwide. We are committed to accelerating the global impact of our science and representing Taiwan’s biotech innovation on the international stage.
RephImmune MAKES HATCHER+ TOP 100 LIST (OCTOBER 2024)
We are proud to announce that RephImmune Biotechnology Inc. has earned a coveted spot on the Hatcher+ Top 100 Global Startups list for October 2024—the world’s first unbiased, AI-powered ranking system for startups worldwide.
The Hatcher+ Top 100 scoring model uses a proprietary system that draws on data from over half a million startups and various funding rounds. This model evaluates core factors such as sector innovation, technological alignment, market position, and growth potential to forecast a startup's success.
“This honor reinforces our commitment to transforming cancer treatment,” said Ming-Wei Chen, CEO of RephImmune.
RephImmune Has Been Selected for SCbioDrive Accelerator
We are honored to announce that RephImmune has been selected as the only Taiwanese company to join the 2024 Fall SCbioDrive Accelerator. As a pioneer in cell and gene therapy, we are excited to gain access to SCbio’s extensive resources, which include connections to over a thousand life sciences organizations. This opportunity will accelerate our cancer immunotherapy innovations and help us expand our impact in the global healthcare market.
RephImmune has been selected as a finalist for the 2024 MassChallenge Switzerland Accelerator
MassChallenge is renowned as one of the world's most prestigious accelerators, and Switzerland is a leading nation in biotechnology and cell & gene therapy. In 2024, MassChallenge Switzerland selected 103 startups from over 1,300 global applicants through a rigorous selection process, representing the top 8% of all applicants. As the only representative from Taiwan, RephImmune's innovative engineered cell therapy has been recognized and honored to join this esteemed group.
https://masschallenge.org/news/masschallenge-switzerland-2024-early-stage-accelerator-cohort/
RephImmune Honored as a Top 10 Winner in the KPMG Taiwan Tech Innovator Competition
RephImmune has successfully been selected as one of the Top 10 finalists in the 2024 KPMG Taiwan Tech Innovator competition, highlighting its innovation and breakthroughs in the field of novel solid tumor cell therapies. Co-hosted by KPMG Taiwan and Meet Startup, this competition aims to identify promising tech innovators in Taiwan and help them expand onto the global stage. Leveraging its cutting-edge technology in cancer treatment, RephImmune has demonstrated its significance in the global life sciences arena. This recognition marks a significant step forward for RephImmune in advancing cancer treatment innovation and provides an opportunity to further engage in KPMG's innovation ecosystem, accelerating the development and application of its technologies.
RephImmune Wins 3rd Place in Health Tech Pitching Competition at SelectUSA Investment Summit
Rephimmune won third place in the Health Technology Competition at the SelectUSA Investment Summit held from June 23-26, 2024. The competition saw participation from 80 startups across 37 global markets. Rephimmune stood out with its revolutionary RACE-T cell therapy, which has the potential to transform cancer treatment.
This honor not only highlights Rephimmune's leading position in the field of cancer therapy research and development but also underscores its commitment to improving treatment outcomes for patients worldwide. The summit attracted applications from over 260 startups globally, making the competition extremely fierce. Rephimmune's success in such a strong field demonstrates the immense potential of its technology.
Rephimmune's achievement lays a solid foundation for future collaborations and investments. As a pioneer in cancer treatment, Rephimmune looks forward to more breakthroughs and innovations, continuing to lead the future of cancer therapy for the benefit of patients worldwide.
https://www.selectusasummit.us/Programming/SelectUSA-Tech
RephImmune Has Been Selected as A Member of The Taiwan Delegation for The 2024 SelectUSA Investment Summit
Led by Ministry of Economic Affairs, AIT, Small and Medium Enterprise and Startup Administration and the TAcc+ accelerator, nineteen Taiwanese companies from various industries will travel to Washington, D.C., to attend the 10th SelectUSA Investment Summit from June 23 to 26. This summit is the premier event for promoting investment in the United States, serving as a bridge between global companies and economic development organizations across the U.S.
Google Sites
Report abuse